Overview

Study of Obeldesivir in Children and Adolescents With COVID-19

Status:
Terminated
Trial end date:
2024-02-23
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19). The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Gilead Sciences